MCID: PST046
MIFTS: 56

Post-Transplant Lymphoproliferative Disease

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Post-Transplant Lymphoproliferative Disease

MalaCards integrated aliases for Post-Transplant Lymphoproliferative Disease:

Name: Post-Transplant Lymphoproliferative Disease 37 49 55
Post-Transplant Lymphoproliferative Disorder 69
Ptld 55

Characteristics:

Orphanet epidemiological data:

55
post-transplant lymphoproliferative disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

Orphanet 55 ORPHA70568
UMLS via Orphanet 70 C0432487
ICD10 via Orphanet 33 D47.9
UMLS 69 C0432487

Summaries for Post-Transplant Lymphoproliferative Disease

MalaCards based summary : Post-Transplant Lymphoproliferative Disease, also known as post-transplant lymphoproliferative disorder, is related to hematopoietic stem cell transplantation and toxoplasmosis. An important gene associated with Post-Transplant Lymphoproliferative Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include liver, b cells and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Post-transplant lymphoproliferative disorder (PTLD) is the name given to a B-cell proliferation due to... more...

Related Diseases for Post-Transplant Lymphoproliferative Disease

Diseases related to Post-Transplant Lymphoproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 30.8 IL10 IL6 TNF
2 toxoplasmosis 30.1 IL10 IL6 TNF
3 pneumonia 29.9 IL10 IL6 TNF
4 graft-versus-host disease 29.7 IL10 IL1A IL6 TNF
5 tonsillitis 29.6 IL1A IL6 LTA TNF
6 lyme disease 11.2
7 punctate inner choroidopathy 10.6 IL10 TNF
8 tropical endomyocardial fibrosis 10.5 IL10 TNF
9 microscopic polyangiitis 10.5 IL10 TNF
10 multifocal choroiditis 10.5 IL10 TNF
11 tungiasis 10.5 IL10 TNF
12 endomyocardial fibrosis 10.5 IL10 TNF
13 skin sarcoidosis 10.5 TNF TNFRSF1B
14 immunoglobulin a deficiency 1 10.4 IL10 LTA
15 posterior scleritis 10.4 TNF TNFRSF10A
16 rheumatoid lung disease 10.4 TNF TNFRSF1B
17 eye lymphoma 10.4 IL10 IL6
18 scorpion envenomation 10.4 IL6 TNF
19 granulomatous dermatitis 10.4 TNF TNFRSF1B
20 choroiditis 10.4 IL10 TNF
21 acute transverse myelitis 10.4 IL10 IL6
22 scleral disease 10.4 TNF TNFRSF1B
23 extramedullary plasmacytoma 10.4 B2M IL6
24 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
25 pustulosis of palm and sole 10.4 TNF TNFRSF1B
26 inflammatory bowel disease 25, autosomal recessive 10.4 IL10 IL10RA
27 critical limb ischemia 10.4 IL6 TNF
28 panuveitis 10.4 IL10 TNF TNFRSF1B
29 chronic gonococcal salpingitis 10.4 TNF TNFRSF1A TNFRSF1B
30 periodic fever, familial, autosomal dominant 10.4 TNF TNFRSF1A TNFRSF1B
31 acute salpingitis 10.4 TNF TNFRSF1A TNFRSF1B
32 chronic salpingitis 10.4 TNF TNFRSF1A TNFRSF1B
33 scabies 10.4 IL10 IL1A
34 exanthem 10.3 TNF TNFRSF1A TNFRSF1B
35 retinitis pigmentosa 75 10.3 TNF TNFRSF1A
36 transient hypogammaglobulinemia 10.3 IL10 LTA TNF
37 guillain-barre syndrome 10.3 TNF TNFRSF1A TNFRSF1B
38 mucocutaneous leishmaniasis 10.3 IL10 LTA TNF
39 idiopathic achalasia 10.3 IL10 LTA TNF
40 leprosy 3 10.3 IL10 SLC11A1 TNF
41 spondylarthropathy 10.3 B2M LTA TNF
42 spondyloarthropathy 1 10.3 TNF TNFRSF1A TNFRSF1B
43 chondromalacia 10.3 TNFRSF10A TNFRSF1B
44 lymphadenitis 10.3 IL10 SLC11A1 TNF
45 lymphoma 10.3
46 cutaneous leishmaniasis 10.3 IL10 SLC11A1 TNF
47 listeriosis 10.3 IL10 IL6 TNF
48 transverse myelitis 10.3 IL10 IL6 TNF
49 immune suppression 10.3 IL10 IL6
50 intermediate uveitis 10.3 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Post-Transplant Lymphoproliferative Disease:



Diseases related to Post-Transplant Lymphoproliferative Disease

Symptoms & Phenotypes for Post-Transplant Lymphoproliferative Disease

GenomeRNAi Phenotypes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 TNFRSF10A TNFRSF1A CASP8 TNFRSF1B FADD TNFSF10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 TNF TNFRSF10A TNFRSF1A CASP8 TNFRSF1B FADD

MGI Mouse Phenotypes related to Post-Transplant Lymphoproliferative Disease:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 FADD B2M IL10 CASP8 TNFRSF1B IL6
2 cardiovascular system MP:0005385 10.35 FADD B2M IL10 CASP8 TNFRSF1B IL6
3 immune system MP:0005387 10.35 FADD B2M IL10 CASP8 TNFRSF1B IL6
4 homeostasis/metabolism MP:0005376 10.34 FADD B2M IL10 CASP8 TNFRSF1B IL10RA
5 endocrine/exocrine gland MP:0005379 10.31 FADD B2M IL10 CASP8 TNFRSF1B IL6
6 cellular MP:0005384 10.3 CASP8 FADD B2M IL10 TNF IL10RA
7 growth/size/body region MP:0005378 10.22 CASP8 IL10 FADD B2M IL1R1 LTA
8 mortality/aging MP:0010768 10.22 FADD B2M IL10 CASP8 TNFRSF1B TNFRSF10A
9 digestive/alimentary MP:0005381 10.2 FADD B2M IL10 TNFRSF1B IL10RA IL6
10 liver/biliary system MP:0005370 10.17 FADD B2M IL10 CASP8 TNFRSF1B IL6
11 integument MP:0010771 10.11 B2M IL10 CASP8 IL6 IL1A TNFRSF1A
12 neoplasm MP:0002006 10.1 B2M IL10 CASP8 TNFRSF1B IL6 TNFRSF10A
13 muscle MP:0005369 9.97 IL10 CASP8 FADD TNF IL6 TNFRSF1A
14 nervous system MP:0003631 9.96 CASP8 IL10 FADD B2M IL1R1 LTA
15 respiratory system MP:0005388 9.76 IL10 CASP8 LTA IL6 TNFRSF1A IL1R1
16 skeleton MP:0005390 9.61 IL10 FADD IL1R1 LTA TNF IL6
17 vision/eye MP:0005391 9.17 TNFRSF1A IL1R1 IL10 TNF LTA IL6

Drugs & Therapeutics for Post-Transplant Lymphoproliferative Disease

Drugs for Post-Transplant Lymphoproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 2 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 2 23214-92-8 31703
3
Fludarabine Approved Phase 4,Phase 2 21679-14-1, 75607-67-9 30751
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
5
Vidarabine Approved, Investigational Phase 4,Phase 2 24356-66-9 21704 32326
6
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
8
Tacrolimus Approved, Investigational Phase 4,Early Phase 1 104987-11-3 445643 439492
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
10
Doxil Approved June 1999 Phase 4,Phase 2 31703
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
13 Alkylating Agents Phase 4,Phase 2
14 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
15 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
16 Anti-Infective Agents Phase 4,Phase 2
17 Antimetabolites Phase 4,Phase 3,Phase 2
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
19 Antiviral Agents Phase 4,Phase 2
20 Topoisomerase Inhibitors Phase 4,Phase 2
21 Calcineurin Inhibitors Phase 4,Phase 2,Early Phase 1
22 Liver Extracts Phase 4,Phase 2,Phase 3
23 Antitubercular Agents Phase 4,Phase 2
24
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
25
Pancrelipase Approved, Investigational Phase 3 53608-75-6
26
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
27
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
28
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
32 Adjuvants, Immunologic Phase 2, Phase 3
33 diuretics Phase 2, Phase 3
34 Hormone Antagonists Phase 2, Phase 3
35 Hormones Phase 2, Phase 3
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
37 pancreatin Phase 3
38 Anti-Inflammatory Agents Phase 3,Phase 2
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2
40 glucocorticoids Phase 3,Phase 2
41 Antiemetics Phase 3,Phase 2
42 Autonomic Agents Phase 3,Phase 2
43 Dermatologic Agents Phase 3,Phase 2
44 Folic Acid Antagonists Phase 3,Phase 2
45 Gastrointestinal Agents Phase 3,Phase 2
46 Methylprednisolone acetate Phase 3,Phase 2
47 Methylprednisolone Hemisuccinate Phase 3,Phase 2
48 Neuroprotective Agents Phase 3,Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
50 Peripheral Nervous System Agents Phase 3,Phase 2

Interventional clinical trials:

(show all 28)

# Name Status NCT ID Phase Drugs
1 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
2 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
3 Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation Unknown status NCT00033475 Phase 3
4 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
5 ATA129 for Allogeneic Hematopoietic Cell Transplant Subjects With EBV-PTLD After Failure of Rituximab Recruiting NCT03392142 Phase 3
6 ATA129 for Solid Organ Transplant Subjects With EBV-PTLD After Failure of Rituximab or Rituximab and Chemotherapy Recruiting NCT03394365 Phase 3
7 To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids Not yet recruiting NCT03371667 Phase 3 Methotrexate;Placebo
8 Bortezomib Plus Rituximab for EBV+ PTLD Completed NCT01058239 Phase 2 bortezomib;rituximab
9 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Completed NCT00064246 Phase 1, Phase 2
10 Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Completed NCT00307125 Phase 2 Rituximab plus immunosuppression;Placebo plus immunosuppression
11 Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy Recruiting NCT02042391 Phase 2 Rituximab sc;Rituximab sc consolidation;Rituximab sc combined with CHOP chemotherapy;Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
12 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas Recruiting NCT02763254 Phase 2
13 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder Active, not recruiting NCT02900976 Phase 2
14 Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation Active, not recruiting NCT00066469 Phase 2 cyclophosphamide;methylprednisolone;prednisone
15 Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Active, not recruiting NCT01964755 Phase 2 Doxorubicin;Methotrexate;Leucovorin;Zidovudine;Rituximab
16 Donor Lymphocyte Infusion After Alternative Donor Transplantation Terminated NCT01027702 Phase 1, Phase 2
17 Pilot Study of Unrelated Cord Blood Transplantation Terminated NCT00916045 Phase 2 Thiotepa;Fludarabine;Intravenous busulphan;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF);Fludarabine;Cyclophosphamide;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF);Fludarabine;Melphalan;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF)
18 Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Terminated NCT00087009 Phase 1
19 Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs Unknown status NCT00947492
20 Virus Surveillance in Pediatric Solid Organ Transplant Recipients Unknown status NCT00886158
21 MMF After Pediatric Liver Transplantation Completed NCT00367146 MMF
22 Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients Completed NCT01375127 Tofacitinib;Tofacitinib
23 Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists Completed NCT00859131 Rabbit Antithymocyte globulin;Daclizumab
24 Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients Recruiting NCT02505789
25 HLA-Identical Sibling Renal Transplant Tolerance Active, not recruiting NCT00619528
26 Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant Not yet recruiting NCT03131934 Early Phase 1
27 Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation Not yet recruiting NCT03343834
28 Relationship Between EBV and PTLD Terminated NCT00215033

Search NIH Clinical Center for Post-Transplant Lymphoproliferative Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Post-Transplant Lymphoproliferative Disease:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Post-Transplant Lymphoproliferative Disease:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Post-Transplant Lymphoproliferative Disease

Anatomical Context for Post-Transplant Lymphoproliferative Disease

MalaCards organs/tissues related to Post-Transplant Lymphoproliferative Disease:

38
Liver, B Cells, T Cells, Lung, Kidney, Heart, Bone

Publications for Post-Transplant Lymphoproliferative Disease

Articles related to Post-Transplant Lymphoproliferative Disease:

(show top 50) (show all 160)
# Title Authors Year
1
Post-transplant lymphoproliferative disease with features of cutaneous natural killer/T-cell lymphoma. ( 29380362 )
2018
2
Post-transplant lymphoproliferative disease after liver transplantation. ( 29313699 )
2018
3
Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. ( 29342279 )
2018
4
Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. ( 29071779 )
2018
5
Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study. ( 28383790 )
2017
6
Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. ( 28906028 )
2017
7
Post-transplant lymphoproliferative disease in liver transplant recipients. ( 28508661 )
2017
8
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
9
Immunotherapy with the trifunctional anti-CD20a88A9a88anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. ( 28093004 )
2017
10
Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review. ( 28780922 )
2017
11
The Role of Antiviral Prophylaxis for the Prevention of Epstein Barr Virus Associated Post-transplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. ( 27545492 )
2016
12
Comment on: Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26944670 )
2016
13
Persistent Epstein-Barr viral load in Epstein-Barr viral naA^ve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease. ( 28058224 )
2016
14
Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease. ( 29421230 )
2016
15
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. ( 27467959 )
2016
16
How Should We Treat Early Post-Transplant Lymphoproliferative Disease After Heart Transplantation? ( 26549285 )
2015
17
Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study. ( 26155195 )
2015
18
FDG-PET/CT in Abdominal Post-Transplant Lymphoproliferative Disease. ( 26544161 )
2015
19
Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. ( 25843801 )
2015
20
Post-transplant lymphoproliferative disease and other malignancies after pediatric cardiac transplantation: an evolving landscape. ( 26262461 )
2015
21
Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. ( 25936966 )
2015
22
Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lymphoproliferative disease of Hodgkin's type: a diagnostic challenge. ( 26239296 )
2015
23
Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report. ( 26361705 )
2015
24
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. ( 25686696 )
2015
25
Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26279197 )
2015
26
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. ( 25845981 )
2015
27
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. ( 24399278 )
2014
28
Array CGH-based analysis of post-transplant plasmacytic hyperplasia reveals 'intact genomes' arguing against categorizing it as part of the post-transplant lymphoproliferative disease spectrum. ( 25041332 )
2014
29
CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target. ( 25242095 )
2014
30
Isolated post-transplantation lymphoproliferative disease involving the breast and axilla as peripheral T-cell lymphoma. ( 24043963 )
2013
31
Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. ( 23802715 )
2013
32
Risk factors for Epstein Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. ( 24056821 )
2013
33
Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease. ( 24335998 )
2013
34
Breast involvement with post-transplant lymphoproliferative disease in a renal transplant recipient. ( 24034058 )
2013
35
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. ( 23737188 )
2013
36
Epistaxis in a kidney transplant recipient: an uncommon presentation of post-transplant lymphoproliferative disease. ( 23577919 )
2013
37
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. ( 22801669 )
2012
38
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. ( 22711849 )
2012
39
Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm. ( 22915052 )
2012
40
Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus. ( 23498038 )
2012
41
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. ( 21584931 )
2012
42
Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease. ( 22554096 )
2012
43
CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. ( 21559814 )
2011
44
Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. ( 21518001 )
2011
45
CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. ( 21275950 )
2011
46
Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. ( 21056103 )
2011
47
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). ( 21294246 )
2011
48
Adult post-transplant lymphoproliferative disease in the liver graft in patients with recurrent hepatitis C. ( 21555941 )
2011
49
Tonsillectomy in post-transplant lymphoproliferative disease in children. ( 20131364 )
2010
50
The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. ( 20070559 )
2010

Variations for Post-Transplant Lymphoproliferative Disease

Expression for Post-Transplant Lymphoproliferative Disease

Search GEO for disease gene expression data for Post-Transplant Lymphoproliferative Disease.

Pathways for Post-Transplant Lymphoproliferative Disease

Pathways related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 B2M CASP8 FADD IL10 IL10RA IL1A
2
Show member pathways
13.88 CASP8 FADD IL6 LTA TNF TNFRSF10A
3
Show member pathways
13.79 CASP8 FADD IL10 IL10RA IL1A IL1R1
4
Show member pathways
13.67 CASP8 IL10 IL10RA IL1A IL1R1 IL6
5
Show member pathways
13.58 IL10 IL10RA IL1A IL1R1 IL6 LTA
6
Show member pathways
13.41 B2M IL10 IL10RA IL1A IL1R1 IL6
7
Show member pathways
13.29 FADD IL10 IL10RA IL1A IL1R1 IL6
8
Show member pathways
13.1 CASP8 IL10 IL10RA IL1A IL1R1 IL6
9
Show member pathways
13.02 CASP8 FADD IL1A IL1R1 IL6 TNF
10
Show member pathways
12.98 CASP8 FADD IL6 TNF TNFRSF1A
11
Show member pathways
12.97 CASP8 FADD IL6 TNF TNFRSF10A TNFRSF1A
12
Show member pathways
12.93 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
13
Show member pathways
12.93 B2M CASP8 FADD IL10 IL1A IL6
14
Show member pathways
12.82 IL6 LTA TNF TNFRSF1A TNFRSF1B
15
Show member pathways
12.81 CASP8 FADD IL1R1 LTA TNF TNFRSF10A
16 12.8 CASP8 IL1A IL1R1 TNF TNFRSF1A
17
Show member pathways
12.79 FADD IL1A IL1R1 IL6 LTA TNF
18
Show member pathways
12.78 CASP8 FADD IL1A IL6 LTA TNF
19
Show member pathways
12.74 IL1A IL1R1 LTA TNF TNFRSF1A TNFRSF1B
20
Show member pathways
12.72 CASP8 FADD IL1R1 TNFRSF10A TNFSF10
21
Show member pathways
12.68 IL10 IL10RA TNF TNFRSF1A TNFRSF1B
22
Show member pathways
12.66 IL10 IL1A IL1R1 IL6 TNF
23
Show member pathways
12.63 CASP8 FADD IL6 TNF TNFRSF1A
24 12.62 B2M IL10 TNF TNFRSF1A TNFRSF1B
25
Show member pathways
12.62 CASP8 FADD IL10 IL6 TNF TNFRSF1A
26
Show member pathways
12.6 IL10 IL10RA IL6 TNF
27
Show member pathways
12.58 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
28 12.5 IL1R1 IL6 LTA TNF TNFRSF1A
29
Show member pathways
12.46 IL10 IL1A IL6 TNF
30
Show member pathways
12.42 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
31
Show member pathways
12.38 CASP8 FADD IL6 TNF
32
Show member pathways
12.37 CASP8 IL10 IL10RA IL1A TNF TNFRSF1A
33
Show member pathways
12.35 CASP8 FADD TNFRSF10A TNFSF10
34
Show member pathways
12.34 CASP8 FADD IL1A TNF TNFRSF1A
35 12.34 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
36
Show member pathways
12.32 IL1A IL1R1 IL6 TNF
37
Show member pathways
12.26 CASP8 FADD IL1A TNF TNFRSF10A TNFRSF1A
38
Show member pathways
12.25 IL10 IL1A IL6 LTA TNF
39 12.24 IL10 IL1A IL6 TNF
40
Show member pathways
12.18 CASP8 FADD TNF TNFRSF1A
41
Show member pathways
12.18 CASP8 FADD IL1A IL1R1 LTA TNF
42 12.16 IL1A IL1R1 TNF TNFRSF1A
43 12.12 IL1A IL1R1 TNF TNFRSF1A
44
Show member pathways
12.1 CASP8 FADD TNF TNFRSF1A
45 12.09 IL10 IL1A IL6 TNF TNFRSF1B
46 12.08 IL1A IL1R1 IL6 TNF
47
Show member pathways
12.03 CASP8 IL1A IL1R1
48
Show member pathways
12.02 IL10 IL6 LTA TNF
49 12.01 CASP8 FADD IL10 IL10RA IL1A IL6
50 12 IL10 IL6 TNF

GO Terms for Post-Transplant Lymphoproliferative Disease

Cellular components related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 IL1R1 SLC11A1 TNF TNFRSF10A TNFRSF1A TNFRSF1B
2 cell surface GO:0009986 9.83 B2M IL1R1 TNF TNFRSF10A TNFRSF1A
3 extracellular space GO:0005615 9.76 B2M IL10 IL1A IL6 LTA TNF
4 ripoptosome GO:0097342 9.37 CASP8 FADD
5 membrane raft GO:0045121 9.35 CASP8 FADD TNF TNFRSF1A TNFRSF1B
6 death-inducing signaling complex GO:0031264 9.32 CASP8 FADD
7 extracellular region GO:0005576 9.32 B2M IL10 IL1A IL1R1 IL6 LTA
8 CD95 death-inducing signaling complex GO:0031265 9.26 CASP8 FADD

Biological processes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.98 TNF TNFRSF10A TNFRSF1A TNFRSF1B
2 defense response to bacterium GO:0042742 9.97 IL10 SLC11A1 TNF TNFRSF1A
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 CASP8 FADD TNF TNFRSF1A TNFSF10
4 cytokine-mediated signaling pathway GO:0019221 9.96 IL10RA IL1A IL1R1 IL6 TNFRSF1A
5 cell surface receptor signaling pathway GO:0007166 9.95 CASP8 FADD IL1R1 TNFRSF10A TNFRSF1A TNFRSF1B
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.93 LTA TNF TNFRSF10A TNFRSF1A TNFRSF1B
7 cellular response to lipopolysaccharide GO:0071222 9.92 IL10 IL6 TNF TNFRSF1B
8 positive regulation of DNA binding transcription factor activity GO:0051091 9.89 IL10 IL6 TNF
9 cellular response to mechanical stimulus GO:0071260 9.89 CASP8 FADD TNFRSF10A TNFRSF1A
10 defense response to Gram-positive bacterium GO:0050830 9.88 IL6 LTA TNF
11 apoptotic signaling pathway GO:0097190 9.88 CASP8 FADD TNF TNFRSF1B
12 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.88 CASP8 FADD TNF TNFRSF10A TNFSF10
13 negative regulation of inflammatory response GO:0050728 9.87 IL10 TNFRSF1A TNFRSF1B
14 inflammatory response GO:0006954 9.86 IL10 IL1A IL6 SLC11A1 TNF TNFRSF10A
15 response to glucocorticoid GO:0051384 9.85 IL10 IL6 TNF
16 positive regulation of interferon-gamma production GO:0032729 9.85 FADD LTA SLC11A1 TNF
17 humoral immune response GO:0006959 9.84 IL6 LTA TNF
18 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.83 TNF TNFRSF1A TNFRSF1B
19 positive regulation of interleukin-6 production GO:0032755 9.83 IL1A IL6 TNF
20 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.83 CASP8 FADD TNFRSF10A TNFSF10
21 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.81 FADD TNF TNFRSF10A TNFRSF1A
22 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.8 CASP8 TNF TNFRSF1A
23 positive regulation of cytokine secretion GO:0050715 9.79 IL10 IL1A TNF
24 negative regulation of growth of symbiont in host GO:0044130 9.75 IL10 LTA TNF
25 positive regulation of proteolysis GO:0045862 9.73 CASP8 FADD
26 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.73 CASP8 FADD TNFRSF10A TNFSF10
27 iron ion transport GO:0006826 9.72 B2M SLC11A1
28 interleukin-1-mediated signaling pathway GO:0070498 9.72 IL1A IL1R1
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF TNFRSF1B
30 lymph node development GO:0048535 9.72 FADD LTA
31 extrinsic apoptotic signaling pathway GO:0097191 9.72 CASP8 FADD TNF TNFRSF10A TNFRSF1B
32 positive regulation of macrophage differentiation GO:0045651 9.71 CASP8 FADD
33 response to molecule of bacterial origin GO:0002237 9.71 B2M IL10
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
35 activation of cysteine-type endopeptidase activity GO:0097202 9.7 CASP8 FADD
36 regulation of necroptotic process GO:0060544 9.7 CASP8 FADD
37 positive regulation of T cell mediated cytotoxicity GO:0001916 9.7 B2M FADD
38 toll-like receptor 3 signaling pathway GO:0034138 9.69 CASP8 FADD
39 positive regulation of ceramide biosynthetic process GO:2000304 9.69 TNF TNFRSF1A
40 negative regulation of lipid storage GO:0010888 9.69 IL6 TNF
41 regulation of synapse organization GO:0050807 9.68 IL10 IL10RA
42 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
43 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF TNFRSF1A
44 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.67 CASP8 FADD TNFRSF10A TNFSF10
45 necroptotic signaling pathway GO:0097527 9.66 FADD TNF
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 IL10 TNF
47 positive regulation of neutrophil extravasation GO:2000391 9.65 IL1A IL1R1
48 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.64 LTA TNF
49 receptor biosynthetic process GO:0032800 9.63 IL10 TNF
50 TRAIL-activated apoptotic signaling pathway GO:0036462 9.63 CASP8 FADD TNFRSF10A

Molecular functions related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.56 FADD IL1R1 TNF TNFRSF10A
2 cytokine activity GO:0005125 9.43 IL10 IL1A IL6 LTA TNF TNFSF10
3 death receptor binding GO:0005123 9.4 CASP8 FADD
4 tumor necrosis factor receptor superfamily binding GO:0032813 9.37 FADD TNFSF10
5 tumor necrosis factor-activated receptor activity GO:0005031 9.33 TNFRSF10A TNFRSF1A TNFRSF1B
6 death effector domain binding GO:0035877 9.32 CASP8 FADD
7 tumor necrosis factor receptor binding GO:0005164 9.02 CASP8 FADD LTA TNF TNFSF10

Sources for Post-Transplant Lymphoproliferative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....